Effect of Ticagrelor vs. Placebo in the reduction of Vaso-occlusive Crises in Pediatric Patients with Sickle Cell Disease - HESTIA3

Study identifier:D5136C00009

ClinicalTrials.gov identifier:NCT03615924

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease (HESTIA3)

Medical condition

Sickle cell disease

Phase

Phase 3

Healthy volunteers

No

Study drug

Ticagrelor, Placebo

Sex

All

Actual Enrollment

193

Study type

Interventional

Age

2 Years - 17 Years

Date

Study Start Date: 26 Sept 2018
Primary Completion Date: 13 Aug 2020
Study Completion Date: 13 Aug 2020

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

IQVIA

Inclusion and exclusion criteria